BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of $5.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-06-30 was $5.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-03-31 was $2.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-06-30 was -$14.00M, a 255.56% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-03-31 was -$19.00M, a 258.33% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2025 was -$31.00M, a 255.00% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2024 was $20.00M, a 233.33% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2023 was $6.00M, a 77.78% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2022 was $27.00M, a 0.00% change from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month as first filed | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month as first filed | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 9 month as first filed | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.00M 10-Q · filed 2026-07-30 | $7.00M 10-Q · filed 2026-07-30 | ||||||
| 2026-03-31 | $2.00M 10-Q · filed 2026-04-30 | |||||||
| 2025-12-31 | -$31.00M 10-K · filed 2026-02-11 | |||||||
| 2025-06-30 | -$14.00M 10-Q · filed 2026-07-30 | -$32.00M 10-Q · filed 2026-07-30 | -$7.00M derived: sum of 3 quarters · filed 2026-07-30 | -$34.00M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | -$19.00M 10-Q · filed 2026-04-30 | $7.00M derived: sum of 2 quarters · filed 2026-04-30 | -$20.00M derived: sum of 3 quarters · filed 2026-04-30 | -$11.00M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$1.00M derived: sum of 2 quarters · filed 2026-02-11 | $8.00M derived: sum of 3 quarters · filed 2026-02-11 | $20.00M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | -$27.00M 10-Q · filed 2024-10-31 | -$18.00M derived: sum of 2 quarters · filed 2024-10-31 | -$6.00M 10-Q · filed 2024-10-31 | -$22.00M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $9.00M 10-Q · filed 2024-07-26 | $21.00M 10-Q · filed 2024-07-26 | $5.00M derived: sum of 3 quarters · filed 2026-02-11 | $22.00M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $12.00M 10-Q · filed 2025-04-24 | -$4.00M derived: sum of 2 quarters · filed 2026-02-11 | $13.00M derived: sum of 3 quarters · filed 2026-02-11 | $20.00M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | -$16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.00M derived: sum of 2 quarters · filed 2026-02-11 | $8.00M derived: sum of 3 quarters · filed 2026-02-11 | $6.00M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $17.00M 10-Q · filed 2024-10-31 | $24.00M derived: sum of 2 quarters · filed 2024-10-31 | $22.00M 10-Q · filed 2024-10-31 | -$3.00M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-06-30 | $7.00M 10-Q · filed 2024-07-26 | $5.00M 10-Q · filed 2024-07-26 | -$20.00M derived: sum of 3 quarters · filed 2025-02-12 | $2.00M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-03-31 | -$2.00M 10-Q · filed 2024-04-25 | -$27.00M derived: sum of 2 quarters · filed 2025-02-12 | -$5.00M derived: sum of 3 quarters · filed 2025-02-12 | $19.00M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2022-12-31 | -$25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$3.00M derived: sum of 2 quarters · filed 2025-02-12 | $21.00M derived: sum of 3 quarters · filed 2025-02-12 | $27.00M 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | $22.00M 10-Q · filed 2023-10-26 | $46.00M derived: sum of 2 quarters · filed 2023-10-26 | $52.00M 10-Q · filed 2023-10-26 | $63.00M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-06-30 | $24.00M 10-Q · filed 2023-07-27 | $30.00M 10-Q · filed 2023-07-27 | $41.00M derived: sum of 3 quarters · filed 2024-02-13 | $46.00M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-03-31 | $6.00M 10-Q · filed 2023-04-27 | $17.00M derived: sum of 2 quarters · filed 2024-02-13 | $22.00M derived: sum of 3 quarters · filed 2024-02-13 | $18.00M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2021-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $16.00M derived: sum of 2 quarters · filed 2024-02-13 | $12.00M derived: sum of 3 quarters · filed 2024-02-13 | $27.00M 10-K · filed 2024-02-13 | ||||
| 2021-09-30 | $5.00M 10-Q · filed 2022-10-26 | $1.00M derived: sum of 2 quarters · filed 2022-10-26 | $16.00M 10-Q · filed 2022-10-26 | $1.00M derived: sum of 4 quarters · filed 2023-02-14 | ||||
| 2021-06-30 | -$4.00M 10-Q · filed 2022-07-27 | $11.00M 10-Q · filed 2022-07-27 | -$4.00M derived: sum of 3 quarters · filed 2023-02-14 | -$15.00M derived: sum of 4 quarters · filed 2023-02-14 | ||||
| 2021-03-31 | $15.00M 10-Q · filed 2022-04-29 | $0.00 derived: sum of 2 quarters · filed 2023-02-14 | -$11.00M derived: sum of 3 quarters · filed 2023-02-14 | -$17.00M derived: sum of 4 quarters · filed 2023-02-14 | ||||
| 2020-12-31 | -$15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$26.00M derived: sum of 2 quarters · filed 2023-02-14 | -$32.00M derived: sum of 3 quarters · filed 2023-02-14 | -$26.00M 10-K · filed 2023-02-14 | ||||
| 2020-09-30 | -$11.00M 10-Q · filed 2021-10-27 | -$17.00M derived: sum of 2 quarters · filed 2021-10-27 | -$11.00M 10-Q · filed 2021-10-27 | -$14.00M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | -$6.00M 10-Q · filed 2021-07-28 | $0.00 10-Q · filed 2021-07-28 | -$3.00M derived: sum of 3 quarters · filed 2022-02-09 | $7.00M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $6.00M 10-Q · filed 2021-04-29 | $3.00M derived: sum of 2 quarters · filed 2022-02-09 | $13.00M derived: sum of 3 quarters · filed 2022-02-09 | $11.00M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | -$3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $7.00M derived: sum of 2 quarters · filed 2022-02-09 | $5.00M derived: sum of 3 quarters · filed 2022-02-09 | $8.00M 10-K · filed 2022-02-09 | ||||
| 2019-09-30 | $10.00M 10-Q · filed 2020-11-05 | $8.00M derived: sum of 2 quarters · filed 2020-11-05 | $11.00M 10-Q · filed 2020-11-05 | $15.00M derived: sum of 4 quarters · filed 2021-02-10 | ||||
| 2019-06-30 | -$2.00M 10-Q · filed 2020-08-06 | $1.00M 10-Q · filed 2020-08-06 | $5.00M derived: sum of 3 quarters · filed 2021-02-10 | $5.00M derived: sum of 4 quarters · filed 2021-02-10 | ||||
| 2019-03-31 | $3.00M 10-Q · filed 2020-05-07 | $7.00M derived: sum of 2 quarters · filed 2021-02-10 | $7.00M derived: sum of 3 quarters · filed 2021-02-10 | $24.00M derived: sum of 4 quarters · filed 2021-02-10 | ||||
| 2018-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $4.00M derived: sum of 2 quarters · filed 2021-02-10 | $21.00M derived: sum of 3 quarters · filed 2021-02-10 | $9.00M 10-K · filed 2021-02-10 | ||||
| 2018-09-30 | $0.00 10-Q · filed 2019-10-31 | $17.00M derived: sum of 2 quarters · filed 2019-10-31 | $5.00M 10-Q · filed 2019-10-31 | -$5.00M 10-Q · filed 2018-10-25 | -$69.00M derived: sum of 4 quarters · filed 2020-02-24 | |||
| 2018-06-30 | $17.00M 10-Q · filed 2019-07-25 | -$17.00M 10-Q · filed 2018-07-26 | $5.00M 10-Q · filed 2019-07-25 | -$5.00M 10-Q · filed 2018-07-26 | -$69.00M derived: sum of 3 quarters · filed 2020-02-24 | -$52.00M derived: sum of 4 quarters · filed 2020-02-24 | ||
| 2018-03-31 | -$12.00M 10-Q · filed 2019-04-25 | $12.00M 10-Q · filed 2018-04-26 | -$86.00M derived: sum of 2 quarters · filed 2020-02-24 | -$69.00M derived: sum of 3 quarters · filed 2020-02-24 | -$58.00M derived: sum of 4 quarters · filed 2020-02-24 | |||
| 2017-12-31 | -$74.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | -$57.00M derived: sum of 2 quarters · filed 2020-02-24 | -$46.00M derived: sum of 3 quarters · filed 2020-02-24 | -$38.00M 10-K · filed 2020-02-24 | $38.00M 10-K · filed 2018-02-13 | |||
| 2017-09-30 | $17.00M 10-Q · filed 2018-10-25 | $28.00M derived: sum of 2 quarters · filed 2018-10-25 | $36.00M 10-Q · filed 2018-10-25 | $35.00M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2017-06-30 | $11.00M 10-Q · filed 2018-07-26 | $19.00M 10-Q · filed 2018-07-26 | $18.00M derived: sum of 3 quarters · filed 2019-02-25 | $21.00M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2017-03-31 | $8.00M 10-Q · filed 2018-04-26 | $7.00M derived: sum of 2 quarters · filed 2019-02-25 | $10.00M derived: sum of 3 quarters · filed 2019-02-25 | $6.00M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2016-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $2.00M derived: sum of 2 quarters · filed 2019-02-25 | -$2.00M derived: sum of 3 quarters · filed 2019-02-25 | $5.00M 10-K · filed 2019-02-25 | -$5.00M 10-K · filed 2017-02-21 | |||
| 2016-09-30 | $3.00M 10-Q · filed 2017-10-26 | -$1.00M derived: sum of 2 quarters · filed 2017-10-26 | $6.00M 10-Q · filed 2017-10-26 | $0.00 derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-06-30 | -$4.00M 10-Q · filed 2017-07-27 | $3.00M 10-Q · filed 2017-07-27 | -$3.00M derived: sum of 3 quarters · filed 2018-02-13 | $2.00M derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-03-31 | $7.00M 10-Q · filed 2017-04-27 | $1.00M derived: sum of 2 quarters · filed 2018-02-13 | $6.00M derived: sum of 3 quarters · filed 2018-02-13 | $0.00 derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2015-12-31 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$1.00M derived: sum of 2 quarters · filed 2018-02-13 | -$7.00M derived: sum of 3 quarters · filed 2018-02-13 | -$22.00M 10-K · filed 2018-02-13 | ||||
| 2015-09-30 | $5.00M 10-Q · filed 2016-10-27 | -$1.00M derived: sum of 2 quarters · filed 2016-10-27 | -$16.00M 10-Q · filed 2016-10-27 | |||||
| 2015-06-30 | -$6.00M 10-Q · filed 2016-07-28 | -$21.00M 10-Q · filed 2016-07-28 | ||||||
| 2015-03-31 | -$15.00M 10-Q · filed 2016-04-28 | |||||||
| 2014-12-31 | -$24.00M 10-K · filed 2017-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |